These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21305612)

  • 21. Duloxetine in the treatment of social anxiety disorder.
    Crippa JA; Filho AS; Freitas MC; Zuardi AW
    J Clin Psychopharmacol; 2007 Jun; 27(3):310. PubMed ID: 17502786
    [No Abstract]   [Full Text] [Related]  

  • 22. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.
    Pollack M; Kinrys G; Krystal A; McCall WV; Roth T; Schaefer K; Rubens R; Roach J; Huang H; Krishnan R
    Arch Gen Psychiatry; 2008 May; 65(5):551-62. PubMed ID: 18458207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
    Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
    Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
    Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
    J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment.
    Blank S; Lenze EJ; Mulsant BH; Dew MA; Karp JF; Shear MK; Houck PR; Miller MD; Pollock BG; Tracey B; Reynolds CF
    J Clin Psychiatry; 2006 Mar; 67(3):468-72. PubMed ID: 16649835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of group cognitive-behavioural therapy plus duloxetine for generalised anxiety disorder versus duloxetine alone.
    Xie ZJ; Han N; Law S; Li ZW; Chen SY; Xiao JP; Zhang Y; Gao BL; Jiang SS; Gao HM; Huang XB
    Acta Neuropsychiatr; 2019 Dec; 31(6):316-324. PubMed ID: 31405402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.
    Hirschfeld RM; Vornik LA
    J Clin Psychiatry; 2004; 65 Suppl 4():46-52. PubMed ID: 15046541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The loudness dependence of the auditory evoked potential (LDAEP) as a predictor of the response to escitalopram in patients with generalized anxiety disorder.
    Park YM; Kim DW; Kim S; Im CH; Lee SH
    Psychopharmacology (Berl); 2011 Feb; 213(2-3):625-32. PubMed ID: 21057773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of generalized anxiety disorder with citalopram.
    Varia I; Rauscher F
    Int Clin Psychopharmacol; 2002 May; 17(3):103-7. PubMed ID: 11981350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.
    Lenze EJ; Rollman BL; Shear MK; Dew MA; Pollock BG; Ciliberti C; Costantino M; Snyder S; Shi P; Spitznagel E; Andreescu C; Butters MA; Reynolds CF
    JAMA; 2009 Jan; 301(3):295-303. PubMed ID: 19155456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels.
    Volonteri LS; Colasanti A; Cerveri G; Fiorentini A; De Gaspari IF; Mauri MC; Valli A; Papa P; Mencacci C
    J Psychopharmacol; 2010 Aug; 24(8):1193-9. PubMed ID: 19406851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder.
    Strawn JR; Prakash A; Zhang Q; Pangallo BA; Stroud CE; Cai N; Findling RL
    J Am Acad Child Adolesc Psychiatry; 2015 Apr; 54(4):283-93. PubMed ID: 25791145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duloxetine treatment of social anxiety disorder with comorbid major depression.
    Lin CC
    J Clin Psychopharmacol; 2008 Oct; 28(5):591-2; author reply 592-3. PubMed ID: 18794669
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment.
    Rickels K; Shiovitz TM; Ramey TS; Weaver JJ; Knapp LE; Miceli JJ
    Int Clin Psychopharmacol; 2012 May; 27(3):142-50. PubMed ID: 22302014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
    Schatzberg AF
    J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.
    Davidson JR; Bose A; Wang Q
    J Clin Psychiatry; 2005 Nov; 66(11):1441-6. PubMed ID: 16420082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.
    Raskin J; George T; Granger RE; Hussain N; Zhao GW; Marangell LB
    J Psychiatr Res; 2012 May; 46(5):667-74. PubMed ID: 22410206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 12-month comparison of brief psychodynamic psychotherapy and pharmacotherapy treatment in subjects with generalised anxiety disorders in a community setting.
    Ferrero A; Pierò A; Fassina S; Massola T; Lanteri A; Daga GA; Fassino S
    Eur Psychiatry; 2007 Nov; 22(8):530-9. PubMed ID: 17900875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.